Depending on whether you do long-term or short-term, Glen's new fund is still in the pharmaceutical sector. In the long run, the pharmaceutical sector will certainly have good returns, and the funds operated by Glen will also have good performance. However, if you want to do short-term, although some pharmaceutical sectors have a callback now, medicine is still at a high valuation.